Page 2 - Declan Doogan News Today

Former FDA head Stephen Hahn is adding a new title to his role at Flagship Pioneering: CEO of the incubator's blood cancer test startup Harbinger Health. Takeda's oncology leader Rachael Brake heads to Corbus as chief scientific officer charged with redefining scope of early-stage pipeline. Goldfinch Bio snags 13-year Ardelyx vet as CSO.

/PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biopharmaceutical company with a portfolio of commercial and innovative,...

Juvenescence Debuts New Product to Aid in Supporting a Healthy Metabolism Metabolic Switch helps consumers support their healthy aging goals News provided by Share this article Share this article DOUGLAS, Isle of Man, April 15, 2021 /PRNewswire/ -- Juvenescence Ltd. (Juvenescence), a life sciences company focused on modifying aging and increasing human health span and longevity, today announced the launch of its first product. Metabolic Switch is an evidence-based, breakthrough C6 Ketone Di-...

Juvenescence Limited: Juvenescence Appoints Dr. Grazia Piizzi as Chief Scientific Officer Dr. Grazia Piizzi, PhD, has joined its Executive Management Team as Chief Scientific Officer. Juvenescence is based on a new understanding of the underlying biological causes of aging, creating evidence-based and science-backed therapies. It is focused on increasing how long people live in health by preventing the diseases of aging in the ?rst place. The Juvenescence team includes highly experienced drug d...

Portage Biotech Divests Portage Pharmaceuticals Limited to Juvenescence Ltd Portage may be entitled to up to USD $244 million in future milestone payments -Toronto, Ontario– – Portage Biotech Inc. a clinical stage immuno-oncology company accelerating research and development to overcome immune resistance, today announced the divestment of its three legacy businesses; Portage Pharmaceuticals Limited including subsidiaries Portage Glasgow Ltd. and EyGen Ltd, to Juvenescence Ltd., a company �...

Published: Mar 02, 2021   New Board appointments strengthen Tenax with world-class expertise in cardiovascular drug development, commercial strategy, and business development New Directors will provide significant guidance as Tenax is poised to advance its two leading drug candidates into late-stage clinical testing Transformational step as Tenax strengthens its positioning as a leading specialty pharmaceutical company focused on cardio-pulmonary therapeutics   a specialty pharmaceutica...

MORRISVILLE –Tenax Therameputics is acquiring an Illinois-based biotech firm with a promising hypertension treatment and named that company’s cofounder as its chief medical officer. Tenax (Nasdaq: TENX) shares soared 38% to $2.45 shortly after the announced deal for PH Precision Med (PHPM) and the appointment of Stuart Rich, MD, as its CMO early Tuesday. Tenax is paying some 12 million shares of stock to PHPM shareholders. PHPM is focused on a potential treatment of pulmonary arterial hyp...

LyGenesis Receives FDA Clearance to Begin Phase 2a Trial of its Cell Therapy for Patients with End Stage Liver Disease, and also Closes $11 Million Convertible Debt Financing News provided by Share this article Share this article PITTSBURGH, Dec. 30, 2020 /PRNewswire/ -- LyGenesis, Inc., a biotechnology company developing cell therapies that enable organ regeneration, announced today that the U.S Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application. Un...